Moberg Pharma AB (publ) - Asset Resilience Ratio
Moberg Pharma AB (publ) (MOB) has an Asset Resilience Ratio of 4.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Moberg Pharma AB (publ) current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Moberg Pharma AB (publ)'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Moberg Pharma AB (publ) (MOB) total assets.
Liquid Assets Composition Over Time
This chart breaks down Moberg Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Moberg Pharma AB (publ)'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr28.33 Million | 4.15% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr28.33 Million | 4.15% |
Asset Resilience Insights
- Limited Liquidity: Moberg Pharma AB (publ) maintains only 4.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Moberg Pharma AB (publ) Industry Peers by Asset Resilience Ratio
Compare Moberg Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Moberg Pharma AB (publ) (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Moberg Pharma AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.15% | Skr28.33 Million ≈ $3.05 Million |
Skr682.26 Million ≈ $73.42 Million |
-0.79pp |
| 2024-12-31 | 4.94% | Skr34.91 Million ≈ $3.76 Million |
Skr706.09 Million ≈ $75.99 Million |
-2.81pp |
| 2023-12-31 | 7.76% | Skr49.25 Million ≈ $5.30 Million |
Skr634.73 Million ≈ $68.31 Million |
-0.80pp |
| 2022-12-31 | 8.55% | Skr48.28 Million ≈ $5.20 Million |
Skr564.42 Million ≈ $60.74 Million |
+0.44pp |
| 2021-12-31 | 8.12% | Skr36.60 Million ≈ $3.94 Million |
Skr450.89 Million ≈ $48.52 Million |
-15.13pp |
| 2020-12-31 | 23.25% | Skr111.73 Million ≈ $12.02 Million |
Skr480.58 Million ≈ $51.72 Million |
-0.36pp |
| 2019-12-31 | 23.61% | Skr30.84 Million ≈ $3.32 Million |
Skr130.59 Million ≈ $14.05 Million |
+22.79pp |
| 2018-12-31 | 0.82% | Skr10.32 Million ≈ $1.11 Million |
Skr1.25 Billion ≈ $134.69 Million |
+0.51pp |
| 2017-12-31 | 0.32% | Skr3.90 Million ≈ $419.44K |
Skr1.22 Billion ≈ $131.64 Million |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.